Have you lost money investing in Sema4 Holdings? If yes, please visit us Sema4 Holdings Corp. Shareholder Class Action or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.

NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP, a nationally recognized investor rights law firm, is reminding investors of the deadline for filing a motion by lead plaintiff in a securities class action lawsuit filed on behalf of investors, holding the securities of Sema4 Holdings Corp. (“Sema4” or the “Company”) purchased or acquired SMFR in between March 14, 2022 and August 15, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the District of Connecticut alleging violations of the Securities Exchange Act of 1934.

Sema4 is a healthcare company that uses artificial intelligence to enable personalized medicine. The company’s platform leverages longitudinal patient data, AI-powered predictive modeling and genomics in combination with other data to deliver better outcomes for patients. Sema4 derives the majority of its sales from diagnostic solutions in women’s health and oncology. Specifically, solutions for women’s health include carrier screening, non-invasive prenatal testing and newborn screening, while solutions for oncology include hereditary cancer testing, molecular profiling and genomic data collection.

Plaintiff alleges that throughout the Class Period, Defendants made materially false and misleading statements. Specifically, Plaintiff alleges that Defendants failed to disclose: (1) that there was a significant risk that Sema4 would reverse a substantial amount of previously recognized revenue that it was unable to recover from third-party payers; (2) that the company experienced decreasing selling prices for its reproductive health segment; and (3) that Sema4’s financial results would be adversely affected as a result of the foregoing.

On August 15, 2022, after the market closes,…